{"entity":{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","aka":[],"tldr":"Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia.","summary":"Eytan Stein led the first-in-human trial of the IDH2 inhibitor enasidenib, which won approval for relapsed IDH2-mutant AML, and was a lead investigator of AUGMENT-101, the trial establishing the menin inhibitor revumenib for KMT2A-rearranged and NPM1-mutant acute leukaemia. He heads the leukaemia service at MSKCC and directs early-phase leukaemia drug development.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib"}],"tags":["aml","menin","idh","early-phase"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":["idh","menin"],"drugs":["revumenib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["augment-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Acute myeloid leukaemia","IDH inhibitors","Menin inhibitors","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib"}],"papers":[{"title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","journal":"Blood","year":2017,"doi":"10.1182/blood-2017-04-779405"},{"title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05812-3"},{"title":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AUGMENT-101%20revumenib%20menin%20inhibitor%20KMT2A%20NPM1%20Issa%20Nature%202023"}]},"route":"/people/eytan-stein/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/"}],"drug":[{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/"}],"paper":[{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}